[Skip to the reading](#reading)

[The chapters](/#chapter-map) [Care routes](/care-chapter/) [Recovery care notebook ](/)

[The bill](/cost-chapter/) [Question sheet](/reader-questions/)

Recovery care notebook / The name

# Find out what the program would actually contain.

Treat the program name as an opening label. The useful details are the problem being assessed, the medicine’s name and the plan for review.

Describe the problem before discussing a product.

## Peptide describes a substance

When an offer says peptide, it means a short linked string of protein building blocks; insulin is one example.

That word alone leaves a lot to ask. What substance is being offered? What is it meant to do for your particular problem? What would count as a reason to change the plan?

For the visit, replace “better recovery” with a task you want to discuss: walking to work, returning to a hobby or sleeping more comfortably.

Read the offer in layers; each layer needs its own answer.

| On the page | What to ask for
| Recovery program | A clear account of what is being assessed and what care is included.
| Peptide therapy | The ingredient name, also called the generic name, rather than a label made for a program.
| Personal plan | What in your history would change the recommendation.
| Ongoing support | Who handles questions and when the plan is reviewed.

## Learn the words before comparing offers

FDA

The U.S. body for drug review is FDA, the Food and Drug Administration.

Compounding

Compounding can involve a pharmacist preparing a patient’s medicine rather than dispensing the drug company’s finished product.

FDA has not approved compounded medicines; that remains the position on September 26, 2026.

A prescription records a licensed prescriber’s order for a drug.

Ask which product would be supplied and which pharmacy would prepare or dispense it.

Keep a copy of the reply. A product name gives you something concrete to discuss at another visit or with the pharmacy.

## Leave with a description you can repeat

Try this question: “Can you explain the plan without using the program name?”

The answer can cover the assessment, the treatment being considered, follow-up and the bill. Write down anything still missing.

Sources and when we checked them

The medicine terms: September 2026. Whether the product has FDA approval: September 26, 2026.

- [FDA’s questions on compounding](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)
- [What FDA approval covers](https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved)

[Earlier chapter Overview](/) [Continue reading Care routes](/care-chapter/)

This notebook is a guide for weighing care choices; it offers neither clinical visits nor products.

[All chapters](/#chapter-map) [Cautions](/safety-chapter/) [Source guide](/source-guide/)